Newsletter Edition #337 [Editorial Update]
Readers,
For a few months every year, interested global health and journalism professionals, from different parts of the world join the Geneva Health Files Fellowship
Newsletter Edition #336 [The Curated Primer]
Readers,
In this edition we bring together the last three months of our reporting on all things Global Health in Geneva.
You will find
Newsletter Edition #156 [Treaty Talks]
Readers,
The negotiations on the Pathogen Access Benefit Sharing system at the WHO, is turning out to be a contest on "Who Blinks First&
Newsletter Edition #155 [Treaty Talks]
Readers,
What is symphony to some, is cacophony to others.
The negotiations on the Pathogen Access Benefit Sharing Mechanisms have registered intense activity by civil
Newsletter Edition #154 [Treaty Talks]
Readers,
Many fault multilateralism for its pace. But one of the interesting aspects of multilateralism is also its unpredictability. We also know that while in
Newsletter Edition #153 [Treaty Talks]
Readers,
We are sharing a guest essay today, ahead of the negotiations on the Pathogen Access Benefit Sharing system at the WHO, that begin tomorrow.
Newsletter Edition #152 [Treaty Talks]
Readers,
Countries will decide next week on who gets access to medical products during health emergencies, and how preparedness and response are determined in the
Newsletter Edition #151 [Treaty Talks]
Readers,
Developing countries have been pushing for the access to technology to make medical products, to better prepare for, and respond to health emergencies. This
Newsletter Edition #335
[GHF Plus: Global Health Policy Intelligence]
This edition was first published on March 13, 2026.
Readers,
In this edition, we bring you a mapping of pharma litigation
Newsletter Edition #150 [Treaty Talks]
Readers,
In today's edition, we bring you an analysis on biosecurity in the context of the current negotiations on the Pathogen Access Benefit
Newsletter Edition #335
[GHF Plus: Global Health Policy Intelligence]
Readers,
In this edition, we bring you a mapping of pharma litigation in 2025. The idea was to give a snapshot